Dry Powder Particle Size Analyses for Dry Powder Processes (Restriction or Recommendation)

Assessing dry powder inhalers

To enable what would otherwise be impractical, invasive and potentially dangerous testing, and to remove the huge variation and costs associated with human subjects, it is common practice to test inhalation devices and formulations using in vitro test apparatus. Industry standard test conditions and relevant parameters have been devised and published by the regulatory authorities and within the...

Dry powder inhaler formulation.

A drug product combines pharmacologic activity with pharmaceutical properties. Desirable performance characteristics are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action. For the dry powder inhaler (DPI), these goals can be met with a suitable powder formulation, an efficient metering system, and ...

Particulate Interactions in Dry Powder Formulations for Inhalation Particulate Interactions in Dry Powder Formulations for Inhalation

DEM Analysis of Particle Adhesion during Powder Mixing for Dry Powder Inhaler Formulation Development

Understanding the adhesive interactions between active pharmaceutical ingredient (API) particles and carrier particles in dry powder inhalers (DPIs) is critical for the development of formulations and process design. In the current study, a discrete element method (DEM), which accounts for particle adhesion, is employed to investigate the attachment processes in DPIs. A critical velocity criter...

Formoterol dry powder in asthma.

We read with interest the paper by Douglas and coworkers (July 1993;48,719-21) on the possible inheritance of sleep disturbed breathing. Investigating 40 first degree relatives of patients with sleep apnoeas, they found a high prevalence of sleep apnoeas/ hypopnoeas (25%), several times higher than the prevalence in a random sample of the British population (5%).' The authors concluded that a f...